Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sherry Niessen

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
Nature Chemical Biology|July 21, 2014
A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitorsBryan R Lanning, Landon R Whitby, Melissa M Dix, et al.
ACS Chemical Biology|January 21, 2015
Selective inhibitor of platelet-activating factor acetylhydrolases 1b2 and 1b3 that impairs cancer cell survivalJae Won Chang, Andrea M Zuhl, Anna E Speers, et al.
Nature Communications|October 12, 2016
Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitorsAndrea M Zuhl, Charles E Nolan, Michael A Brodney, et al.
Science (New York, N.Y.)|February 8, 2014
A structurally distinct human mycoplasma protein that generically blocks antigen-antibody unionRajesh K Grover, Xueyong Zhu, Travis Nieusma, et al.
Journal of Medicinal Chemistry|June 10, 2021
Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of CancerKevin D Freeman-Cook, Robert L Hoffman, Douglas C Behenna, et al.
Journal of Medicinal Chemistry|March 14, 2017
Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFRSimon Planken, Douglas C Behenna, Sajiv K Nair, et al.
Cancer Cell|September 14, 2021
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitorKevin Freeman-Cook, Robert L Hoffman, Nichol Miller, et al.
Journal of Medicinal Chemistry|January 13, 2016
Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR MutantsHengmiao Cheng, Sajiv K Nair, Brion W Murray, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Nature Chemical Biology|July 21, 2014
A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitorsBryan R Lanning, Landon R Whitby, Melissa M Dix, et al.
ACS Chemical Biology|January 21, 2015
Selective inhibitor of platelet-activating factor acetylhydrolases 1b2 and 1b3 that impairs cancer cell survivalJae Won Chang, Andrea M Zuhl, Anna E Speers, et al.
Nature Communications|October 12, 2016
Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitorsAndrea M Zuhl, Charles E Nolan, Michael A Brodney, et al.
Science (New York, N.Y.)|February 8, 2014
A structurally distinct human mycoplasma protein that generically blocks antigen-antibody unionRajesh K Grover, Xueyong Zhu, Travis Nieusma, et al.
Journal of Medicinal Chemistry|June 10, 2021
Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of CancerKevin D Freeman-Cook, Robert L Hoffman, Douglas C Behenna, et al.
Journal of Medicinal Chemistry|March 14, 2017
Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFRSimon Planken, Douglas C Behenna, Sajiv K Nair, et al.
Cancer Cell|September 14, 2021
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitorKevin Freeman-Cook, Robert L Hoffman, Nichol Miller, et al.
Journal of Medicinal Chemistry|January 13, 2016
Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR MutantsHengmiao Cheng, Sajiv K Nair, Brion W Murray, et al.
Pageof 8